Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study

The Lancet Oncology

Volumn 9, Issue 5, 2008, Pages 435-444

  Pfreundschuh, Michael ^a   Ho, Anthony D ^b   Cavallin Stahl, Eva ^c   Wolf, Max ^d   Pettengell, Ruth ^e   Vasova, Ingrid ^f   Belch, Andrew ^g   Walewski, Jan ^h   Zinzani, Pier Luigi ⁱ   Mingrone, Walter ^j   Kvaloy, Stein ^k   Shpilberg, Ofer ^l   Jaeger, Ulrich ^m   Hansen, Mads ⁿ   Corrado, Claudia ^o   Scheliga, Adriana ^p   Loeffler, Markus ^q   Kuhnt, Evelyn ^q  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c LUND UNIVERSITY   (Sweden)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^f UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^g CROSS CANCER INSTITUTE   (Canada)

^h INSTITUTE OF ONCOLOGY   (Poland)

ⁱ Institute of Haematology   (Italy)

^j CANTONAL HOSPITAL AARAU   (Switzerland)

^k Radium Hospital   (Norway)

^l BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^m UNIVERSITY OF VIENNA   (Austria)

ⁿ H S Rijkshospitalet   (Denmark)

^o Fundacion para Combatir La Leucemia   (Argentina)

^p INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^q UNIVERSITY OF LEIPZIG   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; B CELL LYMPHOMA; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EXPLORATORY RESEARCH; HUMAN; INFORMED CONSENT; LINEAR REGRESSION ANALYSIS; LOG RANK TEST; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; NEOPLASM STAGING; PATIENT SELECTION; PREDNISONE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; VINCRISTINE;

EID: 42649113874     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70078-0     Document Type: Article

References (47)

1. Pfreundschuh M., Truemper L., Osterborg A., et al. CHOP-like chemotherapy plus rituximab compared with CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized controlled trial by the Mabthera International Trial (MInT) Group. Lancet Oncol 7 (2006) 379-391
2. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329 (1993) 987-994
3. Harris N., Jaffe E., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting. Airlie House, Virginia, November 1997. J Clin Oncol 17 (1999) 3835-3849
4. Cheson B., Horning S., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 17 (1999) 1244
5. Pfreundschuh M., Trumper L., Kloess M., et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104 (2004) 634-641
6. Shipp M., Harrington D., Klatt M., et al. Identification of major prognostic subgroups of patients with large-cell lymphoma treated with m-BACOD or M-BACOD. Ann Intern Med 104 (1986) 757-765
7. Klein J., and Moeschberger M. Survival analysis: techniques for censored and truncated data (1997), Springer Verlag, New York 333-337
8. Hurvich C., Simonoff J., and Tsai C.-L. Smoothing parameter selection in nonparametric regression using an improved Akaike information criterion. J R Stat Soc 60 (1998) 271-293
9. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (2002) 235-242
10. Sehn L., Donaldson J., Chhanabhai M., et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 23 (2005) 5027-5033
11. Miller T., LeBlanc M., Spier C., et al. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: Update of the Southwest Oncology Group randomized trial. Blood 98 (2001) 724a
12. Miller T., Unger J., Spier C., et al. Effect of adding rituximab to three cycles of CHOP plus involved-field radiotherapy for limited-stage aggressive diffuse B-cell lymphoma (SWOG-0014). Blood 104 (2004) 48a
13. Fisher R., DeVita Jr. V., Johnson B., Simon R., and Young R. Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. Am J Med 63 (1977) 177-182
14. Cabanillas F., Burke J., Smith T., Moon T., Butler J., and Rodriguez V. Factors predicting for response and survival in adults with advanced non-Hodgkin's lymphoma. Arch Intern Med 138 (1978) 413-418
15. Gospodarowicz M., Bush R., Brown T., and Chua T. Prognostic factors in nodular lymphomas: a multivariate analysis based on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys 10 (1984) 489-497
16. Mauch P., Leonard R., Skarin A., et al. Improved survival following combined radiation therapy and chemotherapy for unfavorable prognosis stage I-II non-Hodgkin's lymphomas. J Clin Oncol 3 (1985) 1301-1308
17. Armitage J., Weisenburger D., Hutchins M., et al. Chemotherapy for diffuse large-cell lymphoma-rapidly responding patients have more durable remissions. J Clin Oncol 4 (1986) 160-164
18. Bernstein J., Coleman C., Strickler J., Dorfman R., and Rosenberg S. Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). J Clin Oncol 4 (1986) 847-858
19. Tubiana M., Carde P., Burgers J., Cosset J., Van Glabbeke M., and Somers R. Prognostic factors in non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 12 (1986) 503-514
20. Kaminski M., Coleman C., Colby T., Cox R., and Rosenberg S. Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann Intern Med 104 (1986) 747-756
21. Jagannath S., Velasquez W., Tucker S., et al. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol 4 (1986) 859-865
22. Jacobson J., Aisenberg A., Lamarre L., et al. Mediastinal large cell lymphoma. An uncommon subset of adult lymphoma curable with combined modality therapy. Cancer 62 (1988) 1893-1898
23. Coiffier B., Gisselbrecht C., Vose J., et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol 9 (1991) 211-219
24. Straus D., Wong G., Yahalom J., Varsos G., Gulati S., and Clarkson B. Diffuse large cell lymphoma. Prognostic factors with treatment. Leukemia 5 suppl 1 (1991) 32-37
25. Rodriguez J., Cabanillas F., McLaughlin P., et al. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the 'tumor score'. Ann Oncol 3 (1992) 711-717
26. Vitolo U., Bertini M., Brusamolino E., et al. MACOP-B treatment in diffuse large-cell lymphoma: identification of prognostic groups in an Italian multicenter study. J Clin Oncol 10 (1992) 219-227
27. Lopez-Guillermo A., Montserrat E., Reverter J., et al. Large-cell lymphoma: a study of prognostic factors and assessment of five recently proposed predictive systems. Leuk Lymphoma 10 (1993) 101-109
28. Johnson P., Whelan J., Longhurst S., et al. Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas. Br J Cancer 67 (1993) 792-797
29. Maksymiuk A., Haines C., Tan L., and Skinnider L. Age-related prognostic factor analysis in non-Hodgkin's lymphoma. Can J Oncol 6 (1996) 435-442
30. Caballero M., Rubio V., Rifon J., et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant 20 (1997) 451-458
31. Federico M., Clo V., Brugiatelli M., et al. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL. Haematologica 83 (1998) 800-811
32. Oguchi M., Ikeda H., Isobe K., et al. Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: a survey of the Japan Lymphoma Radiation Therapy Group. Int J Radiat Oncol Biol Phys 48 (2000) 161-168
33. Wilder R., Rodriguez M., Ha C., et al. Bulky disease is an adverse prognostic factor in patients treated with chemotherapy comprised of cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy for aggressive lymphoma. Cancer 91 (2001) 2440-2446
34. Alici S., Bavbek S., Kaytan E., Eralp Y., and Onat H. Prognostic factors in localized aggressive non-Hodgkin's lymphoma. Am J Clin Oncol 26 (2003) 1-5
35. Hayabuchi N., Shibamoto Y., Nakamura K., et al. Stage I and II aggressive B-cell lymphomas of the head and neck: radiotherapy alone as a treatment option and the usefulness of the new prognostic index B-ALPS. Int J Radiat Oncol Biol Phys 55 (2003) 44-50
36. Lopez-Guillermo A., Colomo L., Jimenez M., et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol 23 (2005) 2797-2804
37. Reyes F., Lepage E., Ganem G., et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 352 (2005) 1197-1205
38. Stewart D., Bahlis N., Valentine K., et al. Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 107 (2006) 4623-4627
39. Dumontet C., Mounier N., Munck J., et al. Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study. Br J Haematol 118 (2002) 210-217
40. Danieu L., Wong G., Koziner B., and Clarkson B. Predictive model for prognosis in advanced diffuse histiocytic lymphoma. Cancer Res 46 (1986) 5372-5379
41. Hoskins P., Ng V., Spinelli J., Klimo P., and Connors J. Prognostic variables in patients with diffuse large-cell lymphoma treated with MACOP-B. J Clin Oncol 9 (1991) 220-226
42. Savage K., Al Rajhi N., Voss N., et al. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann Oncol 17 (2006) 123-130
43. Rube C., Nguyen T., Kloss M., Loeffler M., Trumper L., and Pfreundschuh M. Consolidation radiotherapy to bulky disease in aggressive NHL. First results of the NHL B-94 trial of the DSHNHL. Ann Hematol 80 suppl 3 (2001) B84-B85
44. Habermann T., Weller E., Morrison V., et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24 (2006) 3121-3127
45. Pfreundschuh M., Schubert J., Ziepert M., et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9 (2008) 105-116
46. Aviles A., Delgado S., Nambo M., Alatriste S., and Diaz-Maqueo J. Adjuvant radiotherapy to sites of previous bulky disease in patients stage IV diffuse large cell lymphoma. Int J Radiat Oncol Biol Phys 30 (1994) 799-803
47. Horning S., Weller E., Kim K., et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 22 (2004) 3032-3038